Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BP1003 makes a strong initial showing
June 2019
SHARING OPTIONS:

HOUSTON—Preclinical data from BP1003, which was presented at this year’s AACR annual meeting, shows that the compound has potential for treating pancreatic cancer, non-small cell lung cancer and acute myelogenous leukemia (AML), Bio-Path Holdings Inc. reported recently. BP1003 was found to inhibit cell viability and STAT3 protein expression in AML cells. STAT3 is aberrantly active in cancer cells and plays a role in cancer proliferation and angiogenesis, and also is a key culprit in tumor immune evasion. In ex-vivo testing, combining BP1003 with gemcitabine led to increased efficacy in a subset of patient-derived xenografts (PDX). In an in-vivo study of PDAC PDX models, BP1003 with gemcitabine resulted in tumor regression during the 28-day treatment period, and the anticancer activity was maintained for a further 21 days, even after treatment cessation. In addition, BP1003 was found to successfully penetrate the stroma into pancreatic tumors in preclinical models.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.